MeSH tree: D02.203.200
Cancer-fighting T cells do not simply "run out of energy." They are molecularly reprogrammed. For years, mitochondrial dysfunction has been recognized as a hallmark of exhausted T cells in tumors. Yet how metabolic stress ...
Mar 18, 2026
0
11
For more than a year, Diane Hunter, now 72, had been experiencing vague symptoms—pain in her spine and hips, nausea, exhaustion, thirst, and frequent urination. Her primary care physician had ruled out diabetes before finally ...
Nov 11, 2025
0
17
People diagnosed with multiple myeloma—one of the most common forms of blood cancer—are now living nearly twice as long on average as they were in 2005, according to a new study.
Sep 4, 2025
0
15
For patients with newly diagnosed multiple myeloma (NDMM) receiving dexamethasone induction, dose reductions do not negatively impact survival, according to a study published online Jan. 2 in Blood.
Jan 24, 2025
0
17
A team of researchers from the Translational Oncology Research Centre (TORC) of Vrije Universiteit Brussel (VUB), in collaboration with leading German universities, has developed a new biomaterial with high potential in the ...
Jan 15, 2025
0
18
A new research paper titled "GZ17-6.02 interacts with proteasome inhibitors to kill multiple myeloma cells" has been published in Oncotarget.
Mar 6, 2024
0
24
Researchers from A*STAR's Institute of Molecular and Cell Biology (IMCB) and National Cancer Centre Singapore (NCCS) have discovered how the loss of a gene, PBRM1, can lead to the development of kidney cancer. The work is ...
Jul 28, 2023
0
71
A new review paper was published in Oncotarget, titled "Systemic AL amyloidosis: current approach and future direction."
May 5, 2023
0
48
A study by Indiana University School of Medicine researchers sheds new light on the development and treatment of a rare form of muscular dystrophy. The study's findings were recently published in Nature Communications.
Apr 5, 2023
0
52
A research team of 37 scientists, led by the Technical University of Munich, has developed a method to interrogate drug-induced post-translational modifications (PTMs) in a time and dose-dependent way.
